Fate Therapeutics (FATE)

$3.90 0.24 (5.80%)

16:00 EDT FATE Stock Quote Delayed 30 Minutes

FATE Stock Earnings: Fate Therapeutics Beats EPS, Beats Revenue for Q1 2024

By InvestorPlace Earnings May 9, 2024

FATE stock results show that Fate Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

Billionaire Steve Cohen Is Betting Big on Fate Therapeutics (FATE) Stock

CRISPR Layoffs 2023: Job Cuts Hit Gene-Editing Stocks FATE, TCRR, IPSC

Why Is Fate Therapeutics (FATE) Stock Down 62% Today?

Volume:

Previous Close -

Market Cap 383.70M

PE Ratio -20.53

EPS -0.19

Volume (Avg. Vol.) 1.34M

Day's Range $3.87 - $4.18

52-Week Range $1.63 - $8.83

Dividend & Yield N/A (N/A)

FATE Stock Predictions, Articles, and Fate Therapeutics News

From InvestorPlace
From the Web

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

By William White, InvestorPlace Writer Jan 6, 2023

The final day of trading this week is here and we're starting it off with a look at the biggest pre-market stock movers for Friday!

The 5 Top Stocks Cathie Wood Is Buying Now

By Eddie Pan, InvestorPlace Financial News Writer Aug 15, 2022

Cathie Wood's ETFs have performed well following the release of July's CPI report. Recent Cathie Wood stocks include NVTA, TDOC and RBLX.

Cathie Wood Is Buying Up Red-Hot Fate Therapeutics (FATE) Stock

By Eddie Pan, InvestorPlace Financial News Writer Aug 12, 2022

FATE stock is in focus after Cathie Wood's Ark Invest purchased over 600,000 shares yesterday. This was Ark's first purchase since February.

7 Small-Cap Stocks to Buy Before the Bull Market Returns

By Muslim Farooque, InvestorPlace Contributor Aug 7, 2022

These small-cap stocks to buy before the bull market returns have underperformed the market, but have immense potential for future gains.

7 Cathie Wood Stocks Trading at a Discount Right Now

By Tezcan Gecgil, InvestorPlace Contributor Jul 26, 2022

These seven Cathie Wood stocks are the best choices to buy in June. COIN, FATE, NTLA, MELI, TDOC, TSLA, and ZM can make excellent investments.

7 Biotech Stocks With Catalysts That Go Far Beyond Covid-19 Vaccines

By Louis Navellier and the InvestorPlace Research Staff Mar 12, 2021

If you think ecommerce and digital banking have accelerated in the past year, then you really need to check out promising biotech stocks.

3 Top Drug Stocks to Own In 2020

By Ian Cooper, InvestorPlace Contributor Jan 3, 2020

Some of the biggest catalysts for future growth in drug stocks include the millions of retiring baby boomers, and new innovative treatments for a variety of medical issues.

Fate Therapeutics files $300M mixed securities shelf (NASDAQ:FATE)

From Seeking Alpha Nov 9, 2023

Fate Therapeutics files preliminary prospectus for mixed shelf offering, aiming to raise $300M; not an offer to sell securities.

MVIS, DHC and RUM are among after hour movers (NASDAQ:FATE)

From Seeking Alpha Aug 28, 2023

Gainers: Fate Therapeutics (FATE) +5%. Diversified Healthcare (DHC) +4%

Fate Therapeutics GAAP EPS of -$0.54 beats by $0.06, revenue of $0.93M misses by $4.81M (NASDAQ:FATE)

From Seeking Alpha Aug 8, 2023

Fate Therapeutics press release (NASDAQ:FATE): Q2 GAAP EPS of -$0.54 beats by $0.06.Revenue of $0.93M (-95.0% Y/Y) misses by $4.81M.

Why Shares of Fate Therapeutics Soared This Week

From The Motley Fool Jun 16, 2023

The company's shares bounced back after a stock sale last week.

Fate Therapeutics GAAP EPS of -$0.19 beats by $0.47, revenue of $58.98M beats by $25.45M (NASDAQ:FATE)

From Seeking Alpha May 3, 2023

Fate Therapeutics press release (NASDAQ:FATE): Q1 GAAP EPS of -$0.19 beats by $0.47.Revenue of $58.98M (+220.5% Y/Y) beats by $25.45M.